Screener / SEC EDGAR /CIK 0000886163 /10-K filed Feb 27, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq, OTC Health care · Pharmaceuticals

Ligand Pharmaceuticals Inc LGND

Compare with peers Embed
Why it changed

The biggest changes in the 10-K filed Feb 27, 2026, in management's words

10-K, Item 7

This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.

Operating margin

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

-13.5% to 15.3% (+28.8 pts)

The MD&A has no sentence that names a cause for this change.

Revenue

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

+60.4%

“Total revenue and income increased by $101.0 million, or 60%, to $268.1 million in 2025 compared to $167.1 million in 2024 primarily due to the $52.2 million increase in royalties and $39.4 million increase in contract revenue and income.”

Read it in the 10-K

“Contract revenue and income increased by $39.4 million, with the change primarily due to income from the Pelthos Transaction.”

Read it in the 10-K

Cash from operations

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

-49.1%

The MD&A has no sentence that names a cause for this change.

What management said, year by year

The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)

Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.

Revenue

2 of 2 years explained
  • FY 2025 +60.4%

    “Total revenue and income increased by $101.0 million, or 60%, to $268.1 million in 2025 compared to $167.1 million in 2024 primarily due to the $52.2 million increase in royalties and $39.4 million increase in contract revenue and income.”

    Read it in the FY 2025 10-K

    “Contract revenue and income increased by $39.4 million, with the change primarily due to income from the Pelthos Transaction.”

    Read it in the FY 2025 10-K
  • FY 2024 +27.3%

    “Total revenue and other income increased by $35.8 million, or 27%, to $167.1 million in 2024 compared to $131.3 million in 2023 primarily due to the $23.8 million increase in royalties.”

    Read it in the FY 2024 10-K

    “Contract revenue and other revenue increased by $9.5 million primarily due to milestone payments earned from Verona Pharma upon the approval and commercial launch of Ohtuvayre.”

    Read it in the FY 2024 10-K

Operating margin

0 of 2 years explained
  • FY 2025 +28.8 pts

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 -22.6 pts

    The FY 2024 MD&A has no sentence that names a cause for this change.

Cash from operations

0 of 2 years explained
  • FY 2025 -49.1%

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 +95.8%

    The FY 2024 MD&A has no sentence that names a cause for this change.

Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K

Sources

The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.

Also

Financials: the numbers year by year.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/LGND/export.csv") into a cell.

Next:Accounting checks
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.